Piramal Enterprises' Pharma Solution Division Receives Four CMO Leadership Awards 2015

BOSTON, January 13, 2015 /PRNewswire/ --

Piramal Enterprises' Pharma Solution division, a global leader in contract development and manufacturing (CDMO), was a big winner in the recent CMO Leadership Awards, securing four awards in three key categories: Quality, Reliability, & Regulatory. Respondents from Big Pharma, Mid-sized and Specialty Pharma, and Emerging Pharma, voted Piramal to be amongst the top 10% in these categories.

     (Logo: http://photos.prnewswire.com/prnh/20120516/531613 )

The CMO Leadership Awards by Life Science Leader magazine is based on industry leading research conducted by Nice Insight. Nice Insight surveys over 11,000 industry executives - buyers of outsourced services annually, to determine perception and awareness scores of CMOs for five different attributes (i.e. Innovation, Productivity, Quality, Regulatory, and Reliability). The four categories in which the Pharma Solution division has won are:

• Reliability for Big Pharma
• Reliability for Mid-Size & Specialty Pharma
• Regulatory for Mid-Size & Specialty Pharma
• Quality for Emerging Pharma

Companies achieving top 20 percentile perception scores across these 5 attributes are recognized for their achievement.

For 2015, the research respondents were broken into 5 categories: Big Pharma (BP), Mid-Size & Specialty Pharma (MP), Emerging Pharma (EP), Biotech (BT) and Emerging Biotech (EBT). The top 10% in each of these above categories were chosen as winners of CMO leadership awards. Unlike other industry awards, which are given based on a subjective voting or nomination process, the only votes that count towards the CRO/CMO Leadership Awards are those of the pharmaceutical and biopharmaceutical companies using CRO/CMO services. The research respondents of all categories voted Piramal Enterprises' Pharma Solution division to be amongst the top 10% in these categories.

Mr. Vivek Sharma, CEO - Piramal Pharma Solutions said, "We are delighted to receive this prestigious award and to be recognized in multiple areas and categories. The award serves as a validation of our efforts to keep the customer as the focal point, while emphasizing on project ownership, time delivery and commitment towards quality. This recognition from our clients will further motivate our team as we drive towards becoming the 'partner of choice'. Receiving these awards also showcases our company values of entrepreneurship, expertise and trusteeship."

Piramal Pharma Solutions is known for its capabilities as an integrated solutions provider offering a comprehensive range of services across the drug lifecycle. With a successful performance record of over four decades in API supply, Drug Products, and Drug Discovery services, and with supply facilities in North America, Europe, and Asia, it has established itself as a global market leader.

To serve its partners better, Piramal Pharma Solutions continues to invest in next generation technologies and R&D: recent investments include areas such as Anti-Body Drug Conjugation (ADC), Biocatalysis Center of Excellence, and Advanced Flow Reactor (AFR) systems. In addition to investing $40M in new equipment and technologies, they are also augmenting related infrastructure. Recently the company completed a green field facility ($10M) to double its Discovery Services capacity, and also approved a $20M capacity expansion for Hormonal (Morpeth) and ADC (Grangemouth) manufacturing.  

About Piramal Enterprises Limited  

Piramal Enterprises Limited (PEL) is one of India's large diversified companies, with a presence in healthcare, healthcare information management and financial services. PEL's consolidated revenues were $ 750 million in FY2014, with approx. 70% of revenues from outside India.  

In healthcare, PEL is one of the leading players globally in CRAMS (custom research and manufacturing services) as well as in the critical care segment of inhalation and injectable anaesthetics. It also has a strong presence in the OTC segment in India. The Molecular Imaging Division was formed in 2012 with presence in Europe and the USA.

PEL's healthcare information management business, Decision Resources Group, is amongst the top 20 US market research organizations which provide information services to the healthcare industry.

In financial services, PEL, through its Piramal Fund Management Division, provides comprehensive financing solutions to real estate companies. Its Structured Investments Division invests in various sectors including infrastructure. The total funds under management under these businesses is around $ 2 billion. The Company also has strategic alliances with top global pension funds like CPPIB Credit Investment Inc. and APG Asset Management. PEL has also made long term equity investments of around $1 billion in Shriram Group, a leading financial conglomerate in India.

PEL is listed on the Bombay Stock Exchange and the National Stock Exchange in India.

For media enquiries, please contact: 

PIRAMAL ENTERPRISES: 
Akansha Pradhan / Riddhi Goradia
Corporate Communications, Piramal Group
Contact: +91-22-3351-4082 / 4083
akansha.pradhan@piramal.com / riddhi.goradia@piramal.com        

PUBLIC RELATIONS CONSULTANT:
Sheetal Jobanputra / Candida Pereira
MSLGROUP
Tel: +91-22-33557500
Mobile: +91-7498657712 / +91-9820803237
Sheetal.jobanputra@mslgroup.com / candida.pereira@mslgroup.com 

SOURCE Piramal Enterprises Ltd.